Eli Lilly's lead in the obesity race has grown. Its recent stock performance says otherwise

21 hours ago 1

ARTICLE AD BOX

An Eli Lilly & Co. Zepbound injection pen, March 28, 2024.

Bloomberg | Bloomberg | Getty Images

Eli Lilly investors have received some really good news in recent months with a notable exception of how the stock has performed.

Read Entire Article